Researchers have identified a compound that could block certain life-threatening and hard-to-treat allergic reactions.

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in ...

AB Science will be granted a patent, valid through 2040, covering the medical use of masitinib as a treatment for sickle cell ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response -- which in ...